Two new HA fillers broaden Merz's injectable portfolio against Allergan and Galderma.
Merz secured FDA approval for Belotero Volume (+) and Belotero Intense (+), expanding its hyaluronic acid filler lineup and sharpening competitive positioning against Allergan Aesthetics and Galderma. The new formulations address distinct clinical needs: Volume for substantive augmentation and Intense for fine-line correction and superficial placement.
Belotero's thin-gel technology and low particle size have historically differentiated it in the premium segment, particularly for practitioners seeking smooth, natural integration. The addition of Volume and Intense variants gives Merz a fuller portfolio to compete across cheek, lip, nasolabial fold, and perioral indications—critical for practices seeking single-vendor loyalty and rebate consolidation.
Belotero Volume and Intense expand Merz's injectable arsenal across cheek, lip, and fine-line indications.
For practice economics, multi-product Belotero adoption can improve Alle platform penetration and rebate thresholds. The approvals also signal Merz's commitment to injectable innovation as a counterweight to its device portfolio, which includes Ultherapy and Thermage.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
